Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Aug

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82

Research Finds Supercentenarians Have an Abundance of CD4 CTLs

ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS

FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer

Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer